Hypertension Drug Pipeline Analysis Report 2025

Hypertension, or high blood pressure, is a chronic condition that significantly increases the risk of heart disease, stroke, and kidney failure. It accounts for approximately 1.28 billion cases globally among adults aged 30-79 years. There is a high unmet clinical need for better therapies, as current treatment options, such as ACE inhibitors and beta-blockers, have limitations. The rising focus on novel drug classes, including endothelin receptor antagonists and RNA-based therapies, is supporting pipeline growth. Emerging hypertension drug candidates, such as Firibastat and Aprocitentan, highlight the expanding therapeutic pipeline, promising more effective and targeted treatment options in the coming years.

Report Coverage

The Hypertension Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypertension. The hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypertension treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypertension.

Hypertension Drug Pipeline Outlook

Hypertension, or high blood pressure, occurs when blood exerts excessive force on artery walls. It results from genetics, obesity, high salt intake, stress, and inactivity. Over time, it damages blood vessels and increases the risk of heart disease, stroke, and kidney failure. Often symptomless, it is known as the "silent killer," making regular monitoring essential.

Hypertension is treated with lifestyle changes and medications. Diuretics, ACE inhibitors, beta-blockers, and calcium channel blockers help control blood pressure. A low-sodium diet, exercise, stress reduction, and weight management are crucial. In severe cases, combination therapies or newer drugs are used.

Hypertension Epidemiology

Hypertension affects an estimated 1.28 billion adults aged 30-79 worldwide. In the United States, approximately 120 million adults (48.1%) have hypertension, with 77.4% having uncontrolled cases. In England, 30% of adults are affected, including 15% with untreated hypertension. The Asia-Pacific region reports a prevalence of 10.6%-48.3%, with high-income nations like Japan reaching 48.3%, driving demand for advanced hypertension therapeutic products.

Hypertension – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of hypertension drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Gene Therapies
• RNA-Based Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Hypertension – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total hypertension clinical trials.

Hypertension – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hypertension pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapies, and others. The hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypertension.

Hypertension Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the hypertension drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypertension clinical trials:

• Insmed Incorporated
• Bayer
• Eurofarma Laboratorios S.A.
• Inhibikase Therapeutics, Inc.
• Keros Therapeutics, Inc.
• Merck Sharp & Dohme LLC
• Janssen Pharmaceuticals
• Pfizer
• ADARx Pharmaceuticals, Inc.
• Daewoong Pharmaceutical Co. Ltd.
• Mineralys Therapeutics Inc.
• Hanmi Pharmaceutical Company Limited

Hypertension Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypertension drug candidates.

Drug: Adempas (Riociguat, BAY63-2521)

Riociguat, a guanylate cyclase stimulator, is currently undergoing Phase 4 clinical development. The RIALTO study, sponsored by Bayer, is evaluating the long-term benefits of Riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) from previous Bayer trials. The study aims to assess patient outcomes and continued efficacy. With an estimated enrollment of 25 participants, it is expected to be completed by December 28, 2025.

Drug: Lorundrostat

Lorundrostat, an investigational drug, is being evaluated in a Phase 3 trial sponsored by Mineralys Therapeutics Inc. The trial is examining its blood pressure-lowering effects in patients on 2-5 antihypertensive medications. With around 1,083 participants, the trial is expected to conclude by February 2025, advancing treatment options for resistant hypertension.

Drug: Treprostinil Palmitil

Treprostinil Palmitil Inhalation Powder (TPIP) is being evaluated in a Phase 2b study sponsored by Insmed Incorporated. The study aims to assess the efficacy, safety, and pharmacokinetics of the drug in participants with pulmonary arterial hypertension. The study examines TPIP’s effect on pulmonary vascular resistance. Expected to be completed by July 31, 2025, it will involve approximately 102 participants in a randomized, double-blind, placebo-controlled trial.

Reasons To Buy This Report

The Hypertension Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypertension collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Hypertension – Pipeline Insight Report

• Which companies/institutions are leading the hypertension drug development?
• What is the efficacy and safety profile of hypertension pipeline drugs?
• Which company is leading the hypertension pipeline development activities?
• What is the current hypertension commercial assessment?
• What are the opportunities and challenges present in the hypertension drug pipeline landscape?
• What is the efficacy and safety profile of hypertension pipeline drugs?
• Which company is conducting major trials for hypertension drugs?
• Which companies/institutions are involved in hypertension collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hypertension?

Related Reports

Global Idiopathic Intracranial Hypertension Treatment Market

Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Epidemiology Forecast

Global Clinical Trials Market